MDSpire - Takeaway
From the Journals
Commentary & Perspectives

The New Path to ADCs

Engineering payload selectivity for a better quality of life

  • March 24, 2026

  • 11 min

Share

  • 1

    Panel highlights the importance of improving tolerability in ADC therapies.

  • 2

    Developers urged to focus on patient quality of life rather than just potency.

  • 3

    'Fallen angels' refer to previously failed small molecules that can be repurposed.

  • 4

    Rethinking ADC design to include dual-payload strategies may enhance efficacy.

  • 5

    Current challenges include controlling payload release and internalization for better drug delivery.

Original Source(s)

The New Path to ADCs

  • March 24, 2026

Related Content

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...